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Visual function rather 
than visual acuity
Authors’ reply
We would like to thank Ian Murdoch 
and David Crabb for their important 
letter pointing out the tendency to 
underestimate the global burden of 
glaucoma when focusing solely on 
central vision loss. Glaucoma is the 
leading cause of irreversible vision 
loss globally, whose share of overall 
blindness prevalence has been growing 
steadily as investments have begun to 
pay off in the fight against diseases 
such as cataract and trachoma.1,2
We fully agree that reliance only on 
central vision as an index of disease 
severity is particularly poorly suited to 
accurately estimating the glaucoma 
burden.3 Glaucoma has already done 
substantial harm to the eye and to 
visual function by the time central 
vision is affected. Activities such as 
safe driving might become impossible 
because of loss of peripheral vision 
from glaucoma, long before central 
vision is affected.4 Other substantial 
underestimates also result from this 
approach. As pointed out in the Lancet 
Global Health Commission, many 
individuals with early glaucoma need 
timely treatment to avoid later vision 
loss and certain high-risk groups, 
such as adults aged 40 years and 
older and people of African descent, 
require screening care for the same 
reason.1 All of these demands on the 
health-care system are missed when 
we account for the magnitude of 
glaucoma solely using central vision 
loss as a measure.
Besides more inclusive and sensitive 
measures of glaucoma prevalence and 
the disease’s health-care implications, 
we would also like to highlight again 
the following pressing needs in 
the global response to glaucoma, 
as outlined in the Commission: 
(1) low-cost screening outreach 
models for low-income and middle-
income countries—eg, leveraging 
existing cataract outreach efforts 
and eye-screening programmes for 
patients with diabetes; (2) trials of 
cost-effective, scalable, and locally 
acceptable glaucoma treatments 
that are appropriate for low-
resource settings, such as low-cost 
laser trabeculoplasty; (3) rigorous 
studies of inexpensive interventions 
to improve knowledge about and 
demand for glaucoma care in 
underserved areas; (4) capacity 
strengthening among eye-care 
professionals, particularly in sub-
Saharan Africa and east Asia, 
where the magnitude of glaucoma 
blindness is especially high, to 
improve skills in glaucoma detection 
and management with appropriate 
resourcing of ongoing chronic care 
that is stratified by risk of vision loss; 
and (5) evidence-based advocacy to 
governments to include glaucoma in 
national eye health planning.
We fully agree with Murdoch and 
Crabb that global efforts to reduce the 
glaucoma burden depend heavily on 
an accurate and inclusive accounting 
of its precise extent. We cannot fight 
what we do not know.
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